On the occasion of the Osteology Board Meeting on June 22, 2015 in Zurich, the presidency of the Osteology Foundation was officially handed over from Christoph Hmmerle to Mariano Sanz. Professor Christoph Hmmerle served as president of the Osteology Foundation for 12 years, ever since it was established. Looking back at his term of office, he said in an interview prior to the meeting in Zurich: The Osteology Foundation has grown to be a highly respectable organization over recent years. I think the key elements for this success have been the excellent teamwork among the members of the Foundation Board, the dedication of those working in the office and, very importantly, the support and the academic freedom granted by the Founder. Read the full interview with Christoph Hmmerle Even though his term of office as president of the Osteology Foundation has ended, Christoph Hmmerle will remain a member of the Board for two more years, contributing to the development of the Foundation and its activities with his great experience and knowledge. Professor Mariano Sanz, who in Zurich officially took over as new president of the Osteology Foundation, has been a member of the Board for 12 years, he also served as Chairmen of the Education Committee and Member of the Executive Board for several years. For him, the Foundation and its activities are therefore already familiar - with Mariano Sanz, the Osteology Foundation is in the best hands, said Christoph Hmmerle. Mariano Sanz thanked him, and said that in the past 12 years Christoph Hmmerle has done a superb job. Not only as a result of his vision and work, but also through his personal and social skills has the Foundation become a friendly family of leaders all striving for the same objective, which is to fulfil the mission of the Osteology Foundation. Mariano Sanz does not intend to change the strategy of the Osteology Foundation. We will continue the successful work, and wherever possible extend it to other parts of the world, he said in an interview, and added: we shall consolidate our accomplishments, but at the same time open up to new technologies and improve communications media with the goal of widening our reach in order to better fulfil our mission. Read the full interview with Mariano Sanz

Objectives: Systemic diseases may affect oral tissues by increasing their susceptibility to other diseases or by interfering with healing. Oral bisphosphonates (BP) are commonly prescribed for patients with osteoporosis to arrest bone loss and preserve bone density. The American Association of Oral and Maxillofacial Surgeons (AAOMS) have suggested a cautious approach to implant surgery and extractions for patients receiving bisphosphonate therapy.
Methods: Two dental implants (NucleOSS, TR) were inserted in the mandible of a 78-year-old female. The patient has been taking oral alendronate (Fosamax®, marketed by Merck) as a treatment of postmenopausal osteoporosis disease, during the last 3 years. The dose of the bisphosphonate was one tablet of 70 mg once a week.
Results: Dental implants in the patient was successful with uneventful healing. There is was no differences between baseline and 5-year Examinations at Recall in PPD, BOP, Mobility, and bone loss.
Conclusion: History of oral BP use is not an absolute contraindication for dental implant placement and dental implants can be osseointegrated successfully in this patient population. Great attention should be paid to the regular dental recall for implant-prosthetic restorations.

Male patient *1925, by Zembic (2007-2008). This patient suffering from Alzheimer's disease is in need of a simple but durable replacement for his broken maxillary FPD